Revvity Stock To Test $100 Into Earnings? What to Expect

Revvity Inc. (NYSE: RVTY) is heading into a crucial week, with its third-quarter 2025 earnings release scheduled this morning, before the market opens. The stock closed Friday, October 24th, at $98.89, a 1.35% increase from the previous close, placing it within striking distance of the psychologically important $100 mark.

Wall Street expects Revvity to report EPS of $1.14 on revenue of approximately $699.57 million on the quarter. While these figures represent a 2.24% sales growth Y/Y, the EPS projection would be a decline of more than 10% on the $1.28 printed this time last year. The Revvity stock price has pulled back 15.83% in the past 12 months, yet is 17.45% higher over the past month leading into this morning's print.

The upcoming earnings report will be dissected for insights into the performance of Revvity's key segments: Life Sciences and Diagnostics. Analysts and investors will be paying close attention to how Revvity is navigating headwinds, including fluctuations in diagnostic assay volumes in China and shifting capital spending trends within the broader Life Sciences sector. The company's strategic focus on health science solutions, particularly its translational multi-omics technologies and biomarker identification efforts, remains a central pillar of its long-term growth strategy.

Historically, Revvity has demonstrated a strong track record of exceeding earnings expectations. The company has surpassed estimates in each of the past four quarters, with an average surprise of 6.60%. In the prior quarter, Revvity reported an EPS of $1.18, beating the consensus estimate of $1.14 by $0.04. Revenue for that quarter reached $720.28 million, a 4.1% increase from the same period in the previous year.

The Diagnostics segment played a crucial role, contributing $393 million in revenue, a 4% year-over-year increase. The question now is whether Revvity can maintain this positive momentum despite the projected EPS decline.

Price Targets

Revvity's stock has displayed notable resilience, trading within a 52-week range of $81.36 to $129.50. The stock's 50-day simple moving average (SMA) currently sits at $89.38, while the 200-day SMA is $98.98. The stock price hovering around the 200-day SMA suggests a potential inflection point. A decisive move above $100, supported by strong earnings and positive guidance, could signal a bullish trend. Conversely, a failure to break through this level could lead to a retest of lower support levels.

The upcoming earnings call, hosted by President and CEO Prahlad Singh and CFO Max Krakowiak, will be closely monitored for insights into the company's strategic priorities, operational efficiencies, and outlook for the remainder of the year. There have been two upside revisions to EPS estimates on the period in the month leading in to earnings, although 4 to the downside when looking out to 2026.